赖氨酰氧化酶样蛋白2(LOXL2)调控胆汁淤积中胆管细胞的屏障功能
本研究探讨LOXL2在胆管病中的作用:体外用衰老、缺氧、Abcb4-/-小鼠胆汁和鹅去氧胆酸刺激小鼠胆管上皮细胞,观察LOXL2、SNAIL1、E-cadherin表达及跨上皮电阻;体内比较PSC、原发性胆汁性胆管炎和对照的LOXL2表达及血清水平。结果显示上述刺激诱导LOXL2和SNAIL1、抑制E-cadherin并降低跨上皮电阻,LOX抑制可逆转这些变化;胆管病患者血清LOXL2显著升高,PSC中LOXL2过表达伴中等大小胆管胆管上皮细胞E-cadherin丢失。
要点
- 衰老、缺氧、Abcb4-/-小鼠胆汁和鹅去氧胆酸诱导胆管上皮细胞LOXL2和SNAIL1表达并抑制E-cadherin。
- 上述病理变化可被药物性LOX抑制所逆转。
- 胆管病患者血清LOXL2显著升高,PSC中LOXL2过表达伴中等大小胆管胆管上皮细胞E-cadherin丢失。
核心结论
- 反应性胆管上皮细胞产生LOXL2,导致紧密连接通透性增加,体外可被药物性LOX抑制所改善。
- 反应性胆管上皮细胞、门管区肌成纤维细胞和Kupffer细胞是胆管病中LOXL2的主要来源。
研究设计与样本
- 体外用衰老、缺氧、磷脂缺乏的Abcb4-/-小鼠胆汁和鹅去氧胆酸刺激培养的小鼠胆管上皮细胞,检测LOXL2、SNAIL1和E-cadherin表达及跨上皮电阻,并比较有无LOX抑制。
- 体内研究PSC肝脏、对照和四种小鼠胆管病模型中的LOXL2表达,并比较PSC、继发性硬化性胆管炎、原发性胆汁性胆管炎和对照的血清LOXL2水平。
主要发现
- 细胞衰老、缺氧、Abcb4-/-胆汁和鹅去氧胆酸诱导胆管上皮细胞LOXL2和SNAIL1表达、抑制E-cadherin表达,并显著降低跨上皮电阻。
- 所有上述病理变化均可通过药物性LOX抑制而恢复。
- 小鼠模型显示门管区及与胆管反应相关的LOXL2表达诱导。
- 胆管病患者血清LOXL2水平显著升高。
- PSC中LOXL2表达位于特征性胆管周围洋葱皮样纤维化、胆管反应、Kupffer细胞和纤维间隔;PSC中LOXL2过表达与中等大小胆管胆管上皮细胞E-cadherin丢失相平行。
临床怎么用
- 作者认为研究结果支持在原发性硬化性胆管炎患者中测试抗LOXL2治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The lysyl oxidase-like protein 2 (LOXL2) promotes stabilization of the extracellular matrix, chemotaxis, cell growth and cell mobility. We aimed to (i) identify stimuli of LOXL2 in cholangiopathies, (ii) characterize the effects of LOXL2 on biliary epithelial cells' (BECs) barrier function, (iii) compare LOXL2 expression in primary sclerosing cholangitis (PSC), primary biliary cholangitis, and disease controls, and (iv) to determine LOXL2 expression and its cellular sources in four mouse models of cholangiopathies. METHODS: Cultured murine BECs were challenged with well-known triggers of cellular senescence, hypoxia, phospholipid-deficient Abcb4-/- mouse bile and chenodeoxycholic acid and investigated for LOXL2, SNAIL1 and E-cadherin expression and transepithelial electrical resistance with and without LOX-inhibition. In vivo, LOXL2 expression was studied in PSC livers, and controls and mouse models. We compared LOXL2 serum levels in patients with PSC, secondary SC, primary biliary cholangitis, and controls. RESULTS: Cellular senescence, hypoxia, Abcb4-/- bile and chenodeoxycholic acid induced LOXL2 and SNAIL1 expression, repressed E-cadherin expression, and significantly reduced transepithelial electrical resistance in BECs. Notably, all of the pathological changes could be recovered via pharmacological LOX-inhibition. Mouse models showed induced LOXL2 expression in the portal region and in association with ductular reaction. LOXL2 serum levels were significantly elevated in patients with cholangiopathies. In PSC, LOXL2 expression was located to characteristic periductal onion skin-type fibrosis, ductular reaction, Kupffer cells, and fibrotic septa. Importantly, in PSC, LOXL2 overexpression was paralleled by E-cadherin loss in BECs from medium-sized bile ducts. CONCLUSIONS: Reactive BECs produce LOXL2, resulting in increased tight junction permeability, which can be ameliorated by pharmacological LOX-inhibition in vitro. Reactive BECs, portal myofibroblasts, and Kupffer cells are the main sources of LOXL2 in cholangiopathies. LAY SUMMARY: In this study, we investigate the role of lysyl oxidase-like protein 2 (LOXL2), an enzyme pivotal in the development of organ fibrosis, in the pathogenesis of cholangiopathies (diseases of bile ducts), such as primary sclerosing cholangitis. We found LOXL2 to be expressed in association with bile duct epithelial injury and uncovered mechanisms for its upregulation and the subsequent effects in vitro and in vivo. Our findings support testing of anti-LOXL2 treatment strategies for patients with primary sclerosing cholangitis.
引用
- Pollheimer MJ, Racedo S, Mikels-Vigdal A, et al. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. J Hepatol. 2018. PMID: 29709678. doi:10.1016/j.jhep.2018.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。